Nav: Home

Steroid discovered in dogfish sharks attacks Parkinson's-related toxin in animal model

January 16, 2017

WASHINGTON -- A synthesized steroid mirroring one naturally made by the dogfish shark prevents the buildup of a lethal protein implicated in some neurodegenerative diseases, reports an international research team studying an animal model of Parkinson's disease. The clustering of this protein, alpha-synuclein (α-synuclein), is the hallmark of Parkinson's and dementia with Lewy bodies, suggesting a new potential compound for therapeutic research.

The finding, published online in Proceedings of the National Academy of Sciences, also demonstrated that the synthesized steroid, called squalamine, reduced the toxicity of α-synuclein clumps that already existed.

The pre-clinical study results show that squalamine prevents and eliminates α-synuclein build up inside neurons by unsticking the protein from the inner wall of nerve cells, where it clings and builds up into toxic clumps, researchers say.

The animal model used for this study, C. elegans, is a nematode worm genetically engineered to produce human α-synuclein in its muscles. As these worms age, α-synuclein builds up within their muscle cells causing cell damage and paralysis.

"We could literally see that squalamine, given orally to the worms, did not allow α-synuclein to cluster, and prevented muscular paralysis inside the worms," says the study's co-senior author, Michael Zasloff, MD, PhD, professor of surgery and pediatrics at Georgetown University School of Medicine and scientific director of the MedStar Georgetown Transplant Institute.

The study's lead author, graduate student Michele Perni, and other co-senior authors, Michele Vendruscolo, PhD and Christopher M. Dobson, DPhil, ScD, are from Cambridge University. An additional co-senior author, Adriaan Bax, PhD, is from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH) in Bethesda, Maryland. Scientists from the Netherlands, Italy and Spain also contributed to this research.

Zasloff, an expert in innate immune systems, has been studying squalamine for more than 20 years. He discovered it in dogfish sharks in 1993 and synthesized it in 1995 (in a process that does not involve use of any natural shark tissue). His research, as well as that by other scientists, has established antiviral and anticancer properties of the compound. This is the first study to show it has neurological benefits in in vivo models of Parkinson's.

In Parkinson's disease, α-synuclein, a normal protein present within the nervous system, forms toxic clumps that damage and ultimately destroy the neurons in which they form. Considerable research has been directed at discovering compounds that prevent the formation of these masses, thereby representing potential therapeutics for Parkinson's disease.

In this study, the researchers demonstrated in a series of in vitro experiments that squalamine, a positively charged molecule with a high affinity for negatively charged membranes, could literally "kick off" α-synuclein from negatively charged membranes, where the protein binds, preventing the formation of the toxic clumps.

The research team also showed that squalamine could protect healthy human neuronal cells from being damaged by exposure to pre-formed toxic masses of α-synuclein, by preventing them from adhering to the outer membrane of the neuronal cells.

The researchers then extended these studies to a living system, C. elegans, a well-studied model of Parkinson's disease. "Orally administered squalamine prevented the formation of toxic α-synuclein clumps in this complex animal, and rescued the animal from loss of mobility," Zasloff explains. "This experiment taught us that the basic mechanism demonstrated in vitro achieved the anticipated outcome in an animal."
-end-
The study's co-senior author, Professor Christopher Dobson, DPhil, Master of St John's College, University of Cambridge says, "Squalamine gives us a first generation compound, which we believe that we can incrementally improve through further studies of the underlying mechanism by which it affects the aggregation of alpha-synuclein."

Zasloff says a clinical trial with squalamine in Parkinson's disease is being planned. "Squalamine could be especially suited to work in the gut with the goal of treating the gastrointestinal symptoms of Parkinson's," he adds.

Zasloff is the inventor on a patent application that has been filed related to the technology described in this paper. The other authors report having no personal financial interests related to the study.

Additional authors include Celine Galvagnion, Georg Meisl, Martin B. D. Müller, Pavan K. Challa, Patrick Flagmeier, Samuel I. A. Cohen, Pietro Sormanni, Gabriella T. Heller, Francesco A. Aprile, Tuomas P. J. Knowles, Michele Vendruscolo, Serene W. Chen, Ryan Limbocker and Julius Kirkegaard from the University of Cambridge, England; Alexander S. Maltsev, from NIDDK; Ellen A. Nollen, from the European Research Institute for the Biology of Aging, Groningen, The Netherlands; Roberta Cascella, Cristina Cecchi, and Fabrizio Chiti, from the University of Florence; and Nunilo Cremades, from the University of Zaragoza, Spain.

The study was funded by the NIH Intramural Research Program, the Boehringer Ingelheim Fonds, the European Research Council (ERC), and the Centre for Misfolding Diseases at Cambridge.

About Georgetown University Medical Center

Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health. Connect with GUMC on Facebook (Facebook.com/GUMCUpdate), Twitter (@gumedcenter) and Instagram (@gumedcenter).

Georgetown University Medical Center

Related Neurodegenerative Diseases Articles:

Researchers identify link between birth defect and neurodegenerative diseases
A new study has found a link between neurological birth defects in infants commonly found in pregnant women with diabetes and several neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases.
High school football players, 1956-1970, did not have increase of neurodegenerative diseases
A Mayo Clinic study published online today in Mayo Clinic Proceedings found that varsity football players from 1956 to 1970 did not have an increased risk of degenerative brain diseases compared with athletes in other varsity sports.
Researchers reveal how neurodegenerative diseases spread through the brain
Synapses, the place where brain cells contact one another, play a pivotal role in the transmission of toxic proteins.
Untangling a cause of memory loss in neurodegenerative diseases
In mice genetically engineered to mimic aspects of human tauopathy disorders, the researchers restored some of the learning and memory deficits by blocking caspase-2 activity, which suggests that some of the cognitive loss seen in tauopathies might be reversible.
New impetus for treatment neurodegenerative diseases
Twenty years ago, tumor necrosis factor (TNF) seemed a promising target in the treatment of brain diseases like multiple sclerosis or Alzheimer's Disease.
Study demonstrates role of gut bacteria in neurodegenerative diseases
Research has revealed that exposure to bacterial proteins called amyloid that have structural similarity to brain proteins may lead to an increase in clumping of proteins in the brain.
How do the bugs in your gut affect neurodegenerative and psychiatric diseases?
A growing body of scientific and medical evidence continues to shed light on the complex interaction between metabolic pathways affected by microrganisms living in the human gut and gene expression, immune function, and inflammation that can contribute to a range of cognitive, psychiatric, and neurodegenerative disorders.
Antioxidant therapies may help in the fight against neurodegenerative diseases
A new review examines the potential of antioxidant approaches for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis.
Promising results with new gene therapy approach for treating inherited neurodegenerative diseases
A new gene therapy approach designed to replace the enzyme that is deficient in patients with the inherited neurodegenerative disorders Tay-Sachs and Sandhoff diseases successfully delivered the therapeutic gene to the brains of treated mice, restored enzyme function, and extended survival by about 2.5-fold.
Could a new class of fungicides play a role in autism, neurodegenerative diseases?
Scientists at the UNC School of Medicine have found a class of commonly used fungicides that produce gene expression changes similar to those in people with autism and neurodegenerative conditions, including Alzheimer's disease and Huntington's disease.

Related Neurodegenerative Diseases Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#520 A Closer Look at Objectivism
This week we broach the topic of Objectivism. We'll be speaking with Keith Lockitch, senior fellow at the Ayn Rand Institute, about the philosophy of Objectivism as it's taught through Ayn Rand's writings. Then we'll speak with Denise Cummins, cognitive scientist, author and fellow at the Association for Psychological Science, about the impact of Objectivist ideology on society. Related links: This is what happens when you take Ayn Rand seriously Another Critic Who Doesn’t Care What Rand Thought or Why She Thought It, Only That She’s Wrong Quote is from "A Companion to Ayn Rand"